Allergan has a robust reporting system which can track your purchases throughout the year. The graphic below represents the amount of Botox, Juvederm Latisse, Voluma and breast implants purchased from Allergan over the 2014 year. However, not all these products were delivered in 2014. It is possible that some of these products have a “scheduled” shipment in 2015.Natrelles listed here are breast implants. There are other companies which sell breast implants, such as Mentor. Mentor is the maker of the memory shape implant and is a competitor to Allergan. In our Modesto Plastic Surgery practice, we carry a whole array of Mentor breast implants and have at our use many Natrelle implants.
In 2014, 365 bottles of Botox were purchased.
As for the Juvederm Ultra and Juvederm Ultra Plus and the Juvederm Voluma – those are boxes of the product. There is more than one syringe in a box. More on this topic another day. As for the Latisse, it is in cases – many many Latisse boxes in a case.
Highlights of this letter from the makers of BOTOX:
November 17th, Allergan announced that Actavis will acquire Allergan.
Actavis shares the long standing Allergan commitment to innovation.
The acquisition will probably close in quarter 2 in 2015.
Until then, it is business as usual for Allergan Medical.
Read the rest of the letter:
December 17, 2014
Dear Aesthetic Customers:
I would like to take a moment to thank you for supporting Allergan over many years, and in particular, during the last eight months. Many of you sent letters and emails voicing your support for our company and our priorities. It was your voice that provided the fuel and reinforced the importance of maintaining a culture that continues to bring value to patients and customers.
As you know, on November 17th, we announced that Allergan has entered into a definitive agreement whereby Actavis will acquire Allergan. I am very pleased with this outcome and excited for the next chapter as Actavis is highly committed to the success of the Aesthetic specialty, and to providing new programs to further support the growth of Aesthetics market and your continued success. Importantly, Actavis also shares the long standing Allergan commitment to innovation, and bringing meaningful new products to market.
We expect that the acquisition will close in Q2 2015. Until then, it will remain business as usual for Allergan Medical, with no change to your representative support and continuation of the programs and services that you value, including our Allergan Partner Privileges (APP) program, Brilliant Distinctions, Direct to Consumer Advertising, and Allergan Practice Consulting services.
We know you have choices in the market, and always appreciate your choosing Allergan. We look forward to serving you and your patients during the months ahead and as we combine Allergan with Actavis later in 2015.
Allergan is the company who makes BOTOX, Latisse, and Juvederm. These are three popular products offered at Surgical Artistry. Latisse is a take-home product, unlike BOTOX and Juvederm which are injected (by Dr. Calvin Lee).
AllerganViews: The CEO of Allergan has a blog. “Our Pursuit, Life’s Potential.” That is Allergan’s vision, and every day, around the globe, our more than 11,000 employees work to deliver on this vision. David Pyott is the current CEO, as of the writing of this blog which is Dec 10, 2014.
BOTOX can be used to accentuate the eyes by lessening the wrinkles around the eyes. Two areas of FDA approved usage of Botox around the eyes would be for the Glabellar complex and for the crows feet.
What if the eyelashes were accentuated?
Latisse would make the eyes really stand out beautifully by allowing the lashes to grow longer, thicker and darker. There’s much discussion to Latisse. Consider visting the official Latisse website. Or one of our Modesto Latisse webpages. And there’s more information about us at our Modesto Botox webpage.
If the eyes are windows to the soul. Eyelashes are some pretty impressive window treatments.
Latisse comes in a 3ML or 5ML kit. But Latisse kits are usually not sold at your local Hunter Douglas window covering dealers. You can find them in doctor’s offices, such as ours in Modesto, CA.
I got this letter below from Allergan on 11-19-14 (today) addressing the merging of Actavis and Allergan. Allergan wanted to stress that they would continue a high quality of research and development as they had before. Karla from our office sent me a copy of this email which she got, and she wrote that “It looks like Allergan will become part of Actavis soon. This email confirms it and reaffirms their commitment to continuing research and development.”
Here’s the letter from Allergan, the makers of our cherished Botox, Juvederm, and Latisse. For more information about these products, visit our Modesto Botox and Juvederm page.
November 19, 2014
To our valued customers:
As announced in a press release earlier this week, we are pleased to share that Actavis and Allergan have entered into a definitive agreement under which Actavis will acquire Allergan in a deal valued at approximately $66 billion. Bringing our two companies together represents a powerful strategic combination, creating a dynamic, top 10 global pharmaceutical company.
We anticipate that the acquisition will close in 2Q 2015. Until then, it will be business as usual, with no impact to our operations or the high quality of service that you have come to expect from Allergan. Once the transaction closes, we will notify you of any relevant changes, and it is our goal to minimize any possible impact this could have on you, your patients, and our employees.
Like us, the Actavis culture is centered around innovation and customer service, and investment in R&D will remain one of the top priorities of the integrated company. The combined company will offer a broad portfolio of products in Eye Care, CNS/Neurosciences, Medical Aesthetics/Dermatology/Plastic Surgery, Gastroenterology, Women’s Health and Urology and Anti-infective therapeutic categories, as well as the highest quality generic, branded-generic and Over-the-Counter products. The combined company will provide an exceptional level of R&D support, with approximately $1.7 billion invested annually in brands, generics and biopharmaceuticals aimed at delivering high quality products to address unmet patient needs.
We want to thank you for your support and to assure you that we remain dedicated to exceeding your expectations and delivering products and services that make a difference to you and your patients. We look forward to sharing more details of our combined products and services in the future. In the meantime, if you have any questions, please contact your sales representative or visit our websites at actavis.com and allergan.com.